← Liquidia Corporation (LQDA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Liquidia Corporation (LQDA)
Pharmaceutical Preparations · market cap $6.1B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-02 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Liquidia Corporation (LQDA) is a ~170-person specialty pharma company with a market cap of ~$6.9B focused on pulmonary hypertension. Its lead asset LIQ861 (inhaled treprostinil) is in Phase 3 for primary pulmonary hypertension, with a PDUFA date that passed June 27, 2026 with an unknown outcome per the provided facts. A second Phase 3 asset, L606, targets pulmonary hypertension due to lung disease.
The catalyst path
- 2026-11-02 (est.)Earningsimp 5/10
- 2027-06-13 (est.)PDUFA · Relacorilantimp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| LIQ861 Inhaled Treprostinil | Phase 3 | Primary Pulmonary Hypertension |
| Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) | Phase 2 | Influenza |
| L606 | Phase 3 | Pulmonary Hypertension Due to Lung Disease (Disorder) |
Price & technical context
3-month
-61.9%
6-month
-19.8%
12-month
+32.7%
52-wk range
$21.90–$91.03
vs 50-day MA
-59.3%
vs 200-day MA
-44.2%
Realized vol
106.9%
Max drawdown
-66.8%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LQDA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.